ITRM - MCAP CO - Iterum Therapeutics plc

Iterum Therapeutics plc (ITRM) is building a network of treatments against treatment-resistant bacteria by implementing outpatient therapy to combat pathogens in home settings. The company is developing a line of antibiotics for the treatment of complicated urinary tract infections, which minimizes patent threats. However, the current market capitalization of is subject to binary risk due to its dependence on a single drug. The stock price trend is presented in the chart below.

Investors assess fundamental capital risks through the volatility of a business's market value. For Iterum Therapeutics plc (ITRM), FDA approval of sulopenem and the subsequent commercialization of the drug will be the key growth drivers. The company's market capitalization reflects the aggregate value of all shares at the current price. This price action captures the market's reaction to macroeconomic shifts and the pace of the path to profitability. Analysis of this chart allows for the timely identification of critical asset undervaluation.